Prognostic Value of Long Noncoding RNA ROR in Patients with Cancer in China: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 May 25

PMID 31124961

Citations 3

Authors

Shuai Li

Xin-Can Yue

Chao-Yan Sun

Hai-Yan Qin

Xiao-Yang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: For cancer, it is common that there is usually a dysregulation of the long noncoding RNA regulator of reprogramming (LncRNA ROR). To illustrate the application of LncRNA ROR, which serves as the prognostic marker for the malignant tumors, it is of great importance to conduct a meta-analysis.

Methods: There were 3 databases being applied. The data used were collected before January 5, 2018. These 3 databases include the OVID, PubMed, and Science databse. To further explore the association between the expression and survival of LncRNA ROR, it calculated the 95% confidence intervals (CIs) and hazard ratios (HRs). Meanwhile, the odds ratios (ORs) have been calculated for the evaluation of the correlation between the pathological and expression parameters of LncRNA ROR.

Results: There were 8 researches participated by 720 patients. According to the HR, it has been implied that there was a high LncRNA ROR expression related with the weak disease-free survival (DFS) (HR = 3.48, 95% CI, 2.24-5.41) and overall survival (OS) (HR = 2.47, 95% CI, 1.76-3.47) among the cancer patients with none dramatic heterogeneity. There was also a correlation among lymph node metastasis (OR = 5.38, 95% CI, 2.21-13.12), high tumor stage (OR = 3.80, 95% CI, 1.95-7.41), and larger tumor size (OR = 4.43, 95% CI, 1.26-15.51).

Conclusions: Thus, it can be predicted about the lymph node metastasis and high tumor stage, larger tumor size, DFS, and poor OS based on the high LncRNA ROR. This suggests that high LncRNA ROR can be used as a new indicator of poor prognosis in cancer.

Citing Articles

Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance.

Pena-Flores J, Enriquez-Espinoza D, Muela-Campos D, Alvarez-Ramirez A, Saenz A, Barraza-Gomez A Noncoding RNA. 2023; 9(1).

PMID: 36827545 PMC: 9965135. DOI: 10.3390/ncrna9010012.

Long non-coding RNA receptor activator of nuclear factor-κ B ligand promotes cisplatin resistance in non-small cell lung cancer cells.

Zhu Z, Gong X, Li J, Shi Y, Zhang M Exp Ther Med. 2021; 21(5):518.

PMID: 33815591 PMC: 8014969. DOI: 10.3892/etm.2021.9949.

Emerging Roles of Long Noncoding RNA Regulator of Reprogramming in Cancer Treatment.

Sun D, Ye S Cancer Manag Res. 2020; 12:6103-6112.

PMID: 32765105 PMC: 7382586. DOI: 10.2147/CMAR.S253042.

References

Fan Y, Yan T, Chai Y, Jiang Y, Zhu X . Long noncoding RNA HOTTIP as an independent prognostic marker in cancer. Clin Chim Acta. 2017; 482:224-230. DOI: 10.1016/j.cca.2017.07.031. View

Zhou P, Sun L, Liu D, Liu C, Sun L . Long Non-Coding RNA lincRNA-ROR Promotes the Progression of Colon Cancer and Holds Prognostic Value by Associating with miR-145. Pathol Oncol Res. 2016; 22(4):733-40. DOI: 10.1007/s12253-016-0061-x. View

Shi H, Pu J, Zhou X, Ning Y, Bai C . Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Tumour Biol. 2017; 39(5):1010428317697568. DOI: 10.1177/1010428317697568. View

Zhang A, Zhou N, Huang J, Liu Q, Fukuda K, Ma D . The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2012; 23(3):340-50. PMC: 3587705. DOI: 10.1038/cr.2012.164. View

Johnsson P, Lipovich L, Grander D, Morris K . Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta. 2013; 1840(3):1063-71. PMC: 3909678. DOI: 10.1016/j.bbagen.2013.10.035. View

Du Z, Fei T, Verhaak R, Su Z, Zhang Y, Brown M . Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol. 2013; 20(7):908-13. PMC: 3702647. DOI: 10.1038/nsmb.2591. View

Li C, Lu L, Feng B, Zhang K, Han S, Hou D . The lincRNA-ROR/miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep. 2017; 7(1):4637. PMC: 5498629. DOI: 10.1038/s41598-017-04113-w. View

Arunkumar G, Rao A, Manikandan M, Arun K, Vinothkumar V, Revathidevi S . Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. Tumour Biol. 2017; 39(4):1010428317698366. DOI: 10.1177/1010428317698366. View

Chen X, Pei Z, Peng H, Zheng Z . Exploring the molecular mechanism associated with breast cancer bone metastasis using bioinformatic analysis and microarray genetic interaction network. Medicine (Baltimore). 2018; 97(37):e12032. PMC: 6156059. DOI: 10.1097/MD.0000000000012032. View

10.

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

11.

Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q . lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2014; 13(2):330-8. PMC: 4336811. DOI: 10.1158/1541-7786.MCR-14-0251. View

12.

Fan Y, Ye M, Wu L, Lv S, Wu M, Xiao B . Overexpression of miR-98 inhibits cell invasion in glioma cell lines via downregulation of IKKε. Eur Rev Med Pharmacol Sci. 2015; 19(19):3593-604. View

13.

Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T . ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2015; 7(2):1608-18. PMC: 4811484. DOI: 10.18632/oncotarget.6450. View

14.

Jiang F, Zhou X, Huang J . Long Non-Coding RNA-ROR Mediates the Reprogramming in Cardiac Hypertrophy. PLoS One. 2016; 11(4):e0152767. PMC: 4833345. DOI: 10.1371/journal.pone.0152767. View

15.

Fu Z, Li G, Li Z, Wang Y, Zhao Y, Zheng S . Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Cell Death Discov. 2017; 3:17004. PMC: 5447127. DOI: 10.1038/cddiscovery.2017.4. View

16.

Guan Z, Cao Y, Li Y, Tong W, Zhuo A . Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark. 2017; 21(3):557-563. DOI: 10.3233/CBM-170431. View

17.

Shi J, Zhang W, Tian H, Zhang Q, Men T . lncRNA ROR promotes the proliferation of renal cancer and is negatively associated with favorable prognosis. Mol Med Rep. 2017; 16(6):9561-9566. DOI: 10.3892/mmr.2017.7775. View

18.

Chen Y, Peng Y, Xu Z, Ge B, Xiang X, Zhang T . LncROR Promotes Bladder Cancer Cell Proliferation, Migration, and Epithelial-Mesenchymal Transition. Cell Physiol Biochem. 2017; 41(6):2399-2410. DOI: 10.1159/000475910. View

19.

Zhou Y, Wang D, Pang Q . Long noncoding RNA SPRY4-IT1 is a prognostic factor for poor overall survival and has an oncogenic role in glioma. Eur Rev Med Pharmacol Sci. 2016; 20(14):3035-9. View

20.

Wang S, Zhang M, Wu X, Weng M, Zhou D, Quan Z . Overexpression of LncRNA-ROR predicts a poor outcome in gallbladder cancer patients and promotes the tumor cells proliferation, migration, and invasion. Tumour Biol. 2016; 37(9):12867-12875. DOI: 10.1007/s13277-016-5210-z. View